We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
BPC2.5
BPC-157 Research
Mostly mechanism / observationalLimited safety
12 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most BPC-157 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 1997–2025 with a typical study size of 17 participants.
Based on 12 studies · 29 total participants
Confidence
Low
By outcome
Tendon, ligament & soft-tissue healing
Mostly mechanism / observational5 studies
Wound & ulcer healing
Too few graded studies2 studies
Digestive health
Too few graded studies2 studies
Safety profile
Too few graded studies1 study
Active research area
5 studies in the last 5 years
199720112025
1In Vitro2011
BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. · J Appl Physiol (1985) (2011)
In-vitro / ex-vivo study using rat Achilles-tendon explants and cultured tendon fibroblasts
BPC 157 accelerated fibroblast outgrowth from explants and increased cell survival under H2O2 oxidative stress
Dose-dependently increased fibroblast migration and spreading and induced F-actin formation
A complex protective interaction with both alpha-adrenergic (eg, catecholamine release) and dopaminergic (central) systems could be suggested for both intragastric and intraperitoneal BPC 157 administration.
Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, safe in inflammatory bowel disease clinical trials (GEPPPGKPADDAGLV, M.W. 1419, PL 14736) and wound healing, stable in human gastric juice and has no reported toxicity.
Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L. · Curr Pharm Des (2011)
Review of BPC 157 across the gastrointestinal tract in rat models (esophagus, stomach, duodenum, intestine, liver, pancreas)
Reports protection against alcohol and NSAID lesions and healing of fistulas and short-bowel syndrome in rats
Notes the related sequence PL-14736 (same amino-acid sequence) was used in inflammatory bowel disease clinical trials
Although unregulated and yet readily available for purchase over the internet, there is scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides in tendon, muscle, and cartilage injury.
DeFoor MT, Dekker TJ. · Arthroscopy (2025)
Orthopaedic commentary/review on injectable peptides including BPC-157 for athletes and sports performance
Describes the human pharmacokinetic and clinical evidence as very early and scarce
Emphasizes that BPC-157 is unregulated yet readily purchased online, raising safety, ethical and legal concerns
A total of 544 articles from 1993 to 2024 were identified. After duplicates were removed, 36 studies were included (35 preclinical studies, 1 clinical study).
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, et al. · HSS J (2025)
Independent systematic review (PubMed, Cochrane, Embase to June 2024) from an orthopaedic sports-medicine perspective; 36 included studies were 35 preclinical and only 1 clinical
In preclinical models BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bony injuries via growth-hormone-receptor, angiogenesis and anti-inflammatory pathways
The single human report was a retrospective study where 7 of 12 patients reported relief >6 months after intra-articular BPC-157 for chronic knee pain — graded level IV/V evidence
BPC 157 was concluded to be the most potent angiomodulatory agent, acting through different vasoactive pathways and systems (e.g. NO, VEGF, FAK).
Seiwerth S, Brcic L, Vuletic LB, Kolenc D, Aralica G, Misic M. · Curr Pharm Des (2014)
Review of BPC 157's effects on blood vessels after injury (endothelium damage, clotting, thrombosis, vasoconstriction/dilatation, vasculogenesis, edema)
Describes BPC 157 as a highly potent angiomodulatory agent acting via NO, VEGF and FAK pathways in preclinical models
Explicitly notes blood vessels are 'strongly involved in tumor biology', including neoangiogenesis and metastasis — context for the theoretical tumor concern
This small study suggests that intra-articular injection of BPC-157 helps with multiple types of knee pain.
Lee E, Padgett B. · Altern Ther Health Med (2021)
Retrospective chart review of 17 patients given intra-articular BPC 157 (alone or with thymosin-beta-4) for knee pain; 16 followed up by phone
11 of 12 patients (91.6%) who received BPC 157 alone reported significant improvement; 14 of 16 overall reported relief
Uncontrolled and unblinded, self-reported outcomes, no objective imaging or function measures — the authors call for future studies
12Open-Labeln=12 · very small study2024
This is the first report of intravesical BPC-157 (10 mg) injection to help patients with moderate to severe interstitial cystitis who did not respond to pentosan polysulfate treatment.
Lee E, Walker C, Ayadi B. · Altern Ther Health Med (2024)
Uncontrolled pilot in 12 women with moderate-to-severe interstitial cystitis who had failed pentosan polysulfate
Single procedure of BPC-157 injection (total 10 mg) around bladder inflammation; outcomes by Global Response Assessment
10 of 12 reported complete resolution and 2 of 12 reported ~80% improvement; no dropouts and no adverse events reported